R. Perdrisot

Iron oxide nanoparticles for use as an MRI contrast agent: Pharmacokinetics and metabolism

Daniel Pouliquen, J. J. Le Jeune, R. Perdrisot et al. · Magnetic Resonance Imaging · 1991 · 218 citations

Nanoparticles, Nanomedicine, Engineering +10

Rational design of enkephalinase inhibitors: Substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides

Catherine Llorens‐Cortés, G. Gacel, Jean-Paul Swerts et al. · Biochemical and Biophysical Research Communications · 1980 · 93 citations

Bioorganic Chemistry, Biochemistry, Rational Design +10

Is ‘enkephalinase” identical with ‘angiotensin-converting enzyme’?

Jean-Paul Swerts, R. Perdrisot, Bernard Malfroy et al. · European Journal of Pharmacology · 1979 · 92 citations

Molecular Pharmacology, Medicine, Vascular Pharmacology +4

‘Enkephalinase’ is distinct from brain ‘angiostensin-converting enzyme’

Jean-Paul Swerts, R. Perdrisot, Gilles Patey et al. · European Journal of Pharmacology · 1979 · 70 citations

Molecular Physiology, Molecular Neuroscience, Ependyma +7

Superparamagnetic iron oxide nanoparticles as a liver MRI contrast agent: Contribution of microencapsulation to improved biodistribution

Daniel Pouliquen, R. Perdrisot, A. Ermias et al. · Magnetic Resonance Imaging · 1989 · 69 citations

Nanoparticles, Magnetism, Nanomedicine +9